Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Maternal exposure before pregnancy? 73 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 73 reports of Maternal exposure before pregnancy have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.1% of all adverse event reports for SECUKINUMAB.

73
Reports of Maternal exposure before pregnancy with SECUKINUMAB
0.1%
of all SECUKINUMAB reports
6
Deaths
11
Hospitalizations

How Dangerous Is Maternal exposure before pregnancy From SECUKINUMAB?

Of the 73 reports, 6 (8.2%) resulted in death, 11 (15.1%) required hospitalization, and 6 (8.2%) were considered life-threatening.

Is Maternal exposure before pregnancy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 73 reports have been filed with the FAERS database.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Maternal exposure before pregnancy?

CERTOLIZUMAB PEGOL (1,680) LEVONORGESTREL (557) OCRELIZUMAB (434) METHOTREXATE (267) ETHINYL ESTRADIOL\ETONOGESTREL (257) LEVETIRACETAM (256) CYCLOPHOSPHAMIDE (221) FINGOLIMOD (180) LACOSAMIDE (154) RITUXIMAB (133)

Which SECUKINUMAB Alternatives Have Lower Maternal exposure before pregnancy Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Maternal exposure before pregnancy Reports All Drugs Causing Maternal exposure before pregnancy SECUKINUMAB Demographics